A Future Directions of Renal Cell Carcinoma Treatment: Combination of Immune Checkpoint Inhibition and Carbon Ion Radiotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Aug 2

PMID 39091498

Authors

Zhouhang Zheng

Tianci Yang

Yixuan Li

Pei Qu

Zhiang Shao

Yuan Wang

Wei Chang

Shahzad Muhammad Umar

JuFang Wang

Nan Ding

Wei Wang

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is considered radio- and chemo-resistant. Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical efficacy in advanced RCC. However, the overall response rate of RCC to monotherapy remains limited. Given its immunomodulatory effects, a combination of radiotherapy (RT) with immunotherapy is increasingly used for cancer treatment. Heavy ion radiotherapy, specifically the carbon ion radiotherapy (CIRT), represents an innovative approach to cancer treatment, offering superior physical and biological effectiveness compared to conventional photon radiotherapy and exhibiting obvious advantages in cancer treatment. The combination of CIRT and immunotherapy showed robust effectiveness in preclinical studies of various tumors, thus holds promise for overcoming radiation resistance of RCC and enhancing therapeutic outcomes. Here, we provide a comprehensive review on the biophysical effects of CIRT, the efficacy of combination treatment and the underlying mechanisms involved in, as well as its therapeutic potential specifically within RCC.

Citing Articles

Molecular signature of immune-related new survival predictions for subtype of renal cell carcinomas.

Su X, Huang Y, Wang X, Cui L Transl Androl Urol. 2024; 13(10):2180-2193.

PMID: 39507856 PMC: 11535737. DOI: 10.21037/tau-24-225.

References

Takayasu Y, Kubo N, Shino M, Nikkuni O, Ida S, Musha A . Carbon-ion radiotherapy combined with chemotherapy for head and neck mucosal melanoma: Prospective observational study. Cancer Med. 2019; 8(17):7227-7235. PMC: 6885871. DOI: 10.1002/cam4.2614. View

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

Yamada S, Kamada T, Ebner D, Shinoto M, Terashima K, Isozaki Y . Carbon-Ion Radiation Therapy for Pelvic Recurrence of Rectal Cancer. Int J Radiat Oncol Biol Phys. 2016; 96(1):93-101. DOI: 10.1016/j.ijrobp.2016.04.022. View

Motzer R, Powles T, Burotto M, Escudier B, Bourlon M, Shah A . Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23(7):888-898. PMC: 10305087. DOI: 10.1016/S1470-2045(22)00290-X. View

Durante M, Loeffler J . Charged particles in radiation oncology. Nat Rev Clin Oncol. 2009; 7(1):37-43. DOI: 10.1038/nrclinonc.2009.183. View

Tubin S, Fossati P, Carlino A, Martino G, Gora J, Stock M . Novel Carbon Ion and Proton Partial Irradiation of Recurrent Unresectable Bulky Tumors (Particle-PATHY): Early Indication of Effectiveness and Safety. Cancers (Basel). 2022; 14(9). PMC: 9101845. DOI: 10.3390/cancers14092232. View

Huang Y, Dong Y, Zhao J, Zhang L, Kong L, Lu J . Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines. Ann Transl Med. 2019; 7(20):542. PMC: 6861809. DOI: 10.21037/atm.2019.09.128. View

Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G . Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma. Cancer Sci. 2018; 109(9):2873-2880. PMC: 6125442. DOI: 10.1111/cas.13727. View

Szeto G, Finley S . Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019; 5(7):400-410. PMC: 7467854. DOI: 10.1016/j.trecan.2019.05.010. View

10.

Liang S, Zhou G, Hu W . Research Progress of Heavy Ion Radiotherapy for Non-Small-Cell Lung Cancer. Int J Mol Sci. 2022; 23(4). PMC: 8876478. DOI: 10.3390/ijms23042316. View

11.

Grimaldi A, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V . Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014; 3:e28780. PMC: 4106166. DOI: 10.4161/onci.28780. View

12.

Horn L, Spigel D, Vokes E, Holgado E, Ready N, Steins M . Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933. PMC: 6075826. DOI: 10.1200/JCO.2017.74.3062. View

13.

Formenti S, Demaria S . Systemic effects of local radiotherapy. Lancet Oncol. 2009; 10(7):718-26. PMC: 2782943. DOI: 10.1016/S1470-2045(09)70082-8. View

14.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

15.

DeSelm C, Palomba M, Yahalom J, Hamieh M, Eyquem J, Rajasekhar V . Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Mol Ther. 2018; 26(11):2542-2552. PMC: 6225039. DOI: 10.1016/j.ymthe.2018.09.008. View

16.

Schaue D, McBride W . Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015; 12(9):527-40. PMC: 8396062. DOI: 10.1038/nrclinonc.2015.120. View

17.

Daguenet E, Louati S, Wozny A, Vial N, Gras M, Guy J . Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer. 2020; 123(3):339-348. PMC: 7403362. DOI: 10.1038/s41416-020-0942-3. View

18.

Nomiya T, Tsuji H, Kawamura H, Ohno T, Toyama S, Shioyama Y . A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016; 121(2):288-293. DOI: 10.1016/j.radonc.2016.10.009. View

19.

Qu P, Shao Z, Wang B, He J, Zhang Y, Wei W . MiR-663a Inhibits Radiation-Induced Epithelium-to-Mesenchymal Transition by Targeting TGF-β1. Biomed Environ Sci. 2022; 35(5):437-447. DOI: 10.3967/bes2022.059. View

20.

Thompson R, Dong H, Lohse C, Leibovich B, Blute M, Cheville J . PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007; 13(6):1757-61. DOI: 10.1158/1078-0432.CCR-06-2599. View